Table 3 NSCLC case study. Effects of drugs, in terms of the score defined in “Simulation” Section, on gene mutations
From: MiRNA therapeutics based on logic circuits of biological pathways
Drugs | EGFR | ERBB2 | EML4-ALK | PTEN | KRAS | BRAF | PIK3CA | AKT | MEK | EML4-ALK+p16 | Ranking |
|---|---|---|---|---|---|---|---|---|---|---|---|
Score obtained by a single drug | |||||||||||
Everolimus | 2 → -1 | 1 → -2 | 3 → 0 | 0 → -3 | 2 → -1 | -2 → -2 | 1 → -2 | 0 → -3 | -2 → -2 | 4 → 1 | -15 |
BKM120 | 2 → -1 | 1 → -2 | 3 → 0 | 0 → 0 | 2 → -1 | -2 → -2 | 1 → -3 | 0 → 0 | -2 → -2 | 4 → 1 | -10 |
Alectinib | 2 → 2 | 1 → 1 | 3 → -3 | 0 → 0 | 2 → 2 | -2 → -2 | 1 → 1 | 0 → 0 | -2 → -2 | 4 → -3 | -4 |
Trametinib | 2 → 1 | 1 → 0 | 3 → 2 | 0 → 0 | 2 → 1 | -2 → -3 | 1 → 0 | 0 → 0 | -2 → -3 | 4 → 2 | 0 |
Dabrafenib | 2 → 1 | 1 → 0 | 3 → 2 | 0 → 0 | 2 → 1 | -2 → -3 | 1 → 0 | 0 → 0 | -2 → -2 | 4 → 2 | 1 |
Osimertinib | 2 → -3 | 1 → 1 | 3 → 3 | 0 → 0 | 2 → 2 | -2 → -2 | 1 → 1 | 0 → 0 | -2 → -2 | 4 → 4 | 4 |
Score obtained by the combination of two drugs | |||||||||||
Everolimus | 2 → -1 | 1 → -3 | 3 → -1 | 0 → -3 | 2 → -2 | -2 → -3 | 1 → -3 | 0 → -3 | -2 → -3 | 4 → -1 | -23 |